Arteris, INC Form 4 insider transactions

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold a total of 7,627 shares of common stock in early October 2025, primarily to cover tax liabilities and under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Chief Operating Officer Laurent R. Moll sold 42,516 shares of common stock in early October 2025, primarily under a pre-arranged 10b5-1 trading plan.

Arteris, Inc. President and CEO, K. Charles Janac, reported sales of common stock totaling 18,968 shares in early October 2025, primarily for tax obligations and under a pre-arranged trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold 3,887 shares of common stock on October 2, 2025, at $10.9208 per share to cover tax liabilities from restricted stock unit releases.

Arteris, Inc. Director Joachim Kunkel acquired 1,496 shares of common stock as fully vested restricted stock in lieu of cash retainer fees.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold 5,000 shares of common stock for over $10 per share after exercising options.

Arteris VP and General Counsel Paul Alpern exercised options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Arteris Inc.'s VP and CFO, Nicholas B. Hawkins, sold 3,660 shares of common stock for a weighted average price of $8.6903, executed under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold a total of 2,702 shares of common stock in early September 2025 under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold a total of 12,978 shares of common stock in early September 2025 under a pre-arranged 10b5-1 trading plan.

Arteris President and CEO, K. Charles Janac, sold 2,057 shares of common stock for approximately $8.73 per share under a pre-arranged trading plan.

Arteris Inc. Director Wayne C. Cantwell transferred 228,198 shares of common stock to The Cantwell Living Trust.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, sold 42,692 shares of common stock on September 2, 2025, to cover tax liabilities from restricted stock unit releases.

Arteris, Inc. President and CEO, Janac K Charles, sold 1,246 shares of common stock to cover tax liabilities related to restricted stock unit release.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold 438 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Arteris, Inc.'s VP and General Counsel, Paul L. Alpern, sold 258 shares of common stock to cover tax obligations from restricted stock unit release.

Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported the sale of 50,000 common shares through a pre-arranged 10b5-1 trading plan.

Arteris, Inc. Director Antonio J. Viana sold 6,909 shares of common stock for approximately $14.14 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris Director Saiyed Atiq Raza reported the sale of 63,118 common shares on August 5, 2025, executed under a pre-arranged 10b5-1 trading plan.

Arteris' Chief Operating Officer, Laurent R. Moll, sold 34,400 shares of common stock for approximately $13.57 per share under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s CFO, Nicholas B. Hawkins, sold 11,276 shares of common stock for approximately $13.15 per share under a pre-arranged 10b5-1 trading plan.

Arteris Inc.'s President and CEO, Charles Janac, sold 144,245 shares of common stock for approximately $1.9 million under a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s CFO, Nicholas B. Hawkins, sold 5,638 shares of common stock for a weighted average price of $9.0328 per share, executed under a pre-arranged 10b5-1 trading plan.

Arteris Director Saiyed Atiq Raza sold 29,544 shares of common stock for approximately $10.07 per share through a pre-arranged 10b5-1 trading plan.

Arteris, Inc.'s VP and Chief Financial Officer, Nicholas B. Hawkins, sold 5,638 shares of common stock for approximately $10.50 per share under a Rule 10b5-1 trading plan.

Arteris, Inc.'s Chief Operating Officer, Laurent R. Moll, has filed a Form 4 disclosing a planned sale of 736 common shares on July 29, 2025, under a pre-established 10b5-1 trading plan.

Arteris, Inc. Director and 10% Owner Saiyed Atiq Raza sold 1,136 shares of common stock at $10 per share on July 18, 2025, pursuant to a Rule 10b5-1 trading plan.

Arteris, Inc. Director Joachim Kunkel acquired 1,727 shares of common stock as fully vested restricted stock, representing deferred retainer fees.

Arteris, Inc. President and CEO Charles K. Janac reported the sale of 18,968 shares of common stock in early July, primarily to cover tax liabilities and under a pre-arranged trading plan.

Paul L. Alpern, VP and General Counsel of Arteris, Inc., reported the sale of 6,488 shares of common stock in early July 2025, primarily to cover tax liabilities from restricted stock unit releases and pursuant to a pre-arranged 10b5-1 trading plan.